←
Martin Reck1,026 posts
Martin Reck avatar✓

Martin Reck ✓

@MartinReck2

Working on medicine

◷ Joined June 2019▧ 41 Photos and videos
Jordi Remon avatar
⟳ Martin Reck retweeted
Jordi Remon@JordiRemon·Nov 14

📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca. 📊 mINV-PFS: 22 mo | OS: 40 mo 🚀 Can IO, ADCs & bispecifics move to 1st line? 💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies! 🔗 authors.elsevier.com/a/1o6FL…

Post attachment
International Lung Cancer Summit avatar
⟳ Martin Reck retweeted
International Lung Cancer Summit@LungSummit·Nov 5

Martin Reck (@MartinReck2) presented MDT-BRIDGE at ESMO 2026, where 3 in 4 patients with resectable or borderline resectable NSCLC reached resection after neoadjuvant durvalumab plus chemotherapy. Among the authors are our faculty members Nicolas Girard (@nicogirardcurie) and Andrea Filippi (@AndrearicFili). 🔬 MDT-BRIDGE: neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, n=142 📊 Resection rate 74.6% (descriptive) 📊 R0 resection 96.2% (of resected patients) ⚠️ Gr 3-4 AEs, adjuvant vs consolidation phase 7.4% vs 17.4% ⚠️ Descriptive primary endpoint, with no formal hypothesis test Compare the surgery and chemoradiotherapy pathways in our article. @myESMO lungsummit.org/articles/neoa…

Post attachment
Sanjay Popat avatar
⟳ Martin Reck retweeted
Sanjay Popat@DrSanjayPopat·Oct 28

On a beautiful crisp autumnal London morning, am reflecting on the major practice-changing and development datasets presented @myESMO #ESMO26, the strong @royalmarsdenNHS & @ICR_London faculty leadership, & above all the global friends & colleagues who are making a difference

Post attachment
Hidehito HORINOUCHI avatar
⟳ Martin Reck retweeted
Hidehito HORINOUCHI@HHorinouchi·Oct 26

🔥MDT-BRIDGE: Neoadjuvant durvalumab + chemo in resectable/borderline resectable NSCLC — MDT-guided adaptive approach 🆙 @NatureMedicine #ESMO26 🎯ctDNA CL at C2D1 Had 83.3% PPV for pCR 🎯Pre-Surgery CL: pCR 76.0% vs Non-pCR 20.9% 🎯No EFS Events in Resected Pts With CL vs 12-Mo EFS 88.9% Without CL (n=107) 🎙 @MartinReck2 @DoctorJSpicer ☑️NCT05925530 #LCSM @OncoAlert @Larvol @myESMO @IASLC nature.com/articles/s41591-0…

Post attachmentPost attachmentPost attachmentPost attachment
International Lung Cancer Summit avatar
⟳ Martin Reck retweeted
International Lung Cancer Summit@LungSummit·Oct 26

Our SCLC symposium at ESMO 2026 in Madrid kept the Salamanca Auditorium full to the last talk yesterday, and the overflow room as well. Thank you all for coming. From Solange Peters @peters_solange, Martin Reck @MartinReck2, Giannis Mountzios @g_mountzios and Noemí Reguart @NReguart: thank you for staying with us through all 4 talks. The full recording is online now, with all 4 slide decks and your CME certificate. Free for healthcare professionals 🙂 Recording, slides and certificate: lungsummit.org/featured/sclc… #ESMO26 #SCLC #LungCancer

0:20
Alfredo Addeo MD avatar
⟳ Martin Reck retweeted
Alfredo Addeo MD@Alfdoc2·Oct 26

🔥 Outstanding piece of work published today in Nature Medicine! Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏 The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy? This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients. Congratulations to everyone involved! 👏 🔗 nature.com/articles/s41591-0… Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors #ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch

International Lung Cancer Summit avatar
⟳ Martin Reck retweeted
International Lung Cancer Summit@LungSummit·Oct 26

Thank you, Madrid. Thank you to everyone who joined our SCLC symposium at ESMO 2026, and to Solange Peters, Martin Reck, Giannis Mountzios and Noemí Reguart. Thank you, too, for your questions, from the room and sent ahead. Next: ILCS 2026 in Lausanne on 13 November. We hope to see you there. @peters_solange @MartinReck2 @g_mountzios @NReguart Programme and faculty: lungsummit.org/featured/sclc… #ESMO26 #SCLC #LungCancer

Post attachment
Giannis Mountzios avatar
⟳ Martin Reck retweeted
Giannis Mountzios@g_mountzios·Oct 26

#ESMO26 : A great brainstorming summit on #SCLC organized by @LungSummit in a fully packed auditorium+overflow following yesterday’s announcement of DeLlphi-305; ➡️ The chemoIO landscape in 1L @MartinReck2 ➡️ T-cell engager clinical development @peters_solange ➡️ Management οf CRS and ICANS @g_mountzios ➡️ Sequencing and combinations @NReguart A heartfelt 🙏 for your presence, interaction and tons of questions!!! #ESMOAmbassadors

Post attachmentPost attachmentPost attachmentPost attachment
International Lung Cancer Summit avatar
⟳ Martin Reck retweeted
International Lung Cancer Summit@LungSummit·Oct 20

Most cytokine release syndrome with DLL3-targeted TCEs comes in the first cycle, a different pattern from the immune-related events of ICIs. Giannis Mountzios speaks on managing TCEs at our ESMO 2026 symposium, Sunday 25 October from 13:00. We would like to see you in the Salamanca Auditorium, Hall 10. Questions can go in ahead at grillspeakers.com. @peters_solange @MartinReck2 @g_mountzios @NReguart Add it to your calendar: lungsummit.org/calendar/sclc… Programme and faculty: lungsummit.org/featured/sclc… #ESMO26 #SCLC #LungCancer

Post attachment